Abstract: The present invention relates to compressed tablets for peroral delivery of the cannabinoid cannabidiol (CBD). More particularly, the invention provides a compressed tablet having a tablet weight of 60-1200 mg, said tablet being composed of: 50-95 wt. % of a granulate; 5-50 wt. % of lactose; and 0-30 wt. % of other tablet excipients; wherein the granulate contains: a. 2-15 wt. % of cannabidiol; b. 2-30 wt. % of sucrose fatty acid mono-ester; c. 30-96 wt. % of lactose; and d. 0-25 wt. % of other granulate excipients. The compressed tablets according to the invention can conveniently be used in the treatment of psychosis disorders or anxiety disorders. The invention further provides a method for the manufacture of the compressed tablets.

Abstract: The present invention relates to compressed tablets for peroral delivery of the cannabinoid cannabidiol (CBD). More particularly, the invention provides a compressed tablet having a tablet weight of 60-1200 mg, said tablet being composed of: 50-95 wt. % of a granulate; 5-50 wt. % of lactose; and 0-30 wt. % of other tablet excipients; wherein the granulate contains: a. 2-15 wt. % of cannabidiol; b. 2-30 wt. % of sucrose fatty acid mono-ester; c. 30-96 wt. % of lactose; and d. 0-25 wt. % of other granulate excipients. The compressed tablets according to the invention can conveniently be used in the treatment of psychosis disorders or anxiety disorders. The invention further provides a method for the manufacture of the compressed tablets.

Abstract: The present invention relates to compressed tablets for peroral delivery of the cannabinoid cannabidiol (CBD). More particularly, the invention provides a compressed tablet having a tablet weight of 60-1200 mg, said tablet being composed of: •50-95 wt. % of a granulate; •5-50 wt. % of lactose; and •0-30 wt. % of other tablet excipients; wherein the granulate contains: a.2-15 wt. % of cannabidiol; b.2-30 wt. % of sucrose fatty acid mono-ester; c.30-96 wt. % of lactose; and d.0-25 wt. % of other granulate excipients. The compressed tablets according to the invention can conveniently be used in the treatment of psychosis disorders or anxiety disorders. The invention further provides a method for the manufacture of the compressed tablets.

Abstract: Applicator and method for injecting a bulking agent at one or more selected submucosal positions in a periurethral tissue of a female patients' urethra. The applicator comprises a lance, such as a cystoscope with a distal end provided with one or more optical sensors, and a needle guide with a bore receiving the lance. The needle guide comprises needle channels at different angular positions, each needle channel extending between a needle entrance surface and an opposite shoulder surface. The needle channels are oriented to direct a needle via external peripheral tissue of the urethral meatus to a submucosal position at a urethra section, e.g., within the optical scope of the optical sensor.

Abstract: Applicator for delivering an occluding compound in a fallopian tube includes a lumen extending between a proximal end connectable to a dispenser for containing uncured occluding compound, and a distal end. A spiral wire with a first end is connected to the distal end of the lumen and a free second end. A disconnecting member is configured to disconnect the spiral wire from the distal end. An actuator is configured to actuate the disconnecting member. The distal end of the lumen can be inserted into the fallopian tube. The spiral wire functions as a guide wire. The curable compound embeds the spiral wire. The actuator can be actuated to disconnect the embedded spiral wire from the distal end of the lumen.

Abstract: Applicator for injecting a bulking agent at one or more selected submucosal positions in a periurethral tissue of a female patients' urethra. The applicator comprises a lance, such as a cystoscope with a distal end provided with one or more optical sensors, and a needle guide with a bore receiving the lance. The needle guide comprises needle channels at different angular positions, each needle channel extending between a needle entrance surface and an opposite shoulder surface. The needle channels are oriented to direct a needle via external peripheral tissue of the urethral meatus to a submucosal position at a urethra section, e.g., within the optical scope of the optical sensor.

Abstract: A mixing device for bone cement is provided. The mixing device includes a mixing handle, an housing, and a mixing paddle. The mixing handle having a rod, where at least portions of the rod are in tubular form with monomer inside of the rod. The housing has a mixing chamber in which the monomer and a powder are miscible. The mixing paddle is arranged in the mixing chamber and is movable via the rod.

Abstract: The present invention relates to compressed tablets for peroral delivery of the cannabinoid ?9-tetrahydrocannabinol(THC). More particularly, the invention provides a compressed tablet having a tablet weight of 25-1000 mg, said tablet being composed of: compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment •30-90 wt % of a granulate; •10-70 wt % of lactose; and •0-30 wt % of other tablet excipients; wherein the granulate contains: a.2-5 wt % of ?9-tetrahydrocannabinol; b.2-20 wt % of sucrose fatty acid mono-ester; c.50-96 wt % of lactose; d.0.05-0.6 wt % of antioxidant; and e.0-25 wt % of other granulate excipients. The compressed tablets according to the invention can conveniently be used in the treatment of spasticity and pain caused by multiple sclerosis, neurophatic pain, chronic pain, behavioral disturbance by Alzheimer's disease, stroke, spinal cord injury, peripheral neuropathy, neurogenic pain, nociceptive pain and nausea.

Abstract: The present invention relates to a granulate comprising granules made up of 40-99 wt. % of lactose particles and 1-60 wt. % of a binding component that holds together the lactose particles within the granules. Said granules have a mass weighted average diameter of 50-500 ?m and said binding component is a solid dispersion or a solid solution of 10-75 wt. % of a cannabinoid in 25-80 wt. % of a lipophilic matrix. The lipophilic matrix contains at least 80 wt. % sucrose fatty acid mono-ester, the fatty acid residue being selected from C8-C18 fatty acids. The aforementioned granulate can be processed into oral dosage units in the form of tablets for oral delivery. The invention further provides a method for the manufacture of the granulate.

Abstract: The present invention relates to a granulate comprising granules made up of 40-99 wt. % of lactose particles and 1-60 wt. % of a binding component that holds together the lactose particles within the granules. Said granules have a mass weighted average diameter of 50-500 ?m and said binding component is a solid dispersion or a solid solution of 10-75 wt. % of a cannabinoid in 25-80 wt. % of a lipophilic matrix. The lipophilic matrix contains at least 80 wt. % sucrose fatty acid mono-ester, the fatty acid residue being selected from C8-C18 fatty acids. The aforementioned granulate can be processed into oral dosage units in the form of tablets for oral delivery. The invention further provides a method for the manufacture of the granulate.

Abstract: The present invention relates to compressed tablets for peroral delivery of the cannabinoid cannabidiol (CBD). More particularly, the invention provides a compressed tablet having a tablet weight of 60-1200 mg, said tablet being composed of: 50-95 wt. % of a granulate; 5-50 wt. % of lactose; and 0-30 wt. % of other tablet excipients; wherein the granulate contains: a.2-15 wt. % of cannabidiol; b.2-30 wt. % of sucrose fatty acid mono-ester; c.30-96 wt. % of lactose; and d.0-25 wt. % of other granulate excipients. The compressed tablets according to the invention can conveniently be used in the treatment of psychosis disorders or anxiety disorders. The invention further provides a method for the manufacture of the compressed tablets.

Abstract: The present invention relates to compressed tablets for peroral delivery of the cannabinoid ?9-tetrahydrocannabinol (THC). More particularly, the invention provides a compressed tablet having a tablet weight of 25-1000 mg, said tablet being composed of: compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment 30-90 wt % of a granulate; 10-70 wt % of lactose; and 0-30 wt % of other tablet excipients; wherein the granulate contains: a. 2-5 wt % of ?9-tetrahydrocannabinol; b. 2-20 wt % of sucrose fatty acid mono-ester; c. 50-96 wt % of lactose; d. 0.05-0.6 wt % of antioxidant; and e. 0-25 wt % of other granulate excipients. The compressed tablets according to the invention can conveniently be used in the treatment of spasticity and pain caused by multiple sclerosis, neurophatic pain, chronic pain, behavioral disturbance by Alzheimer's disease, stroke, spinal cord injury, peripheral neuropathy, neurogenic pain, nociceptive pain and nausea.

Abstract: Applicator for injecting a bulking agent at one or more selected submucosal positions in a periurethral tissue of a female patients' urethra. The applicator comprises a lance, such as a cystoscope with a distal end provided with one or more optical sensors, and a needle guide with a bore receiving the lance. The needle guide comprises needle channels at different angular positions, each needle channel extending between a needle entrance surface and an opposite shoulder surface. The needle channels are oriented to direct a needle via external peripheral tissue of the urethral meatus to a submucosal position at a urethra section, e.g., within the optical scope of the optical sensor.

Abstract: The present invention relates to a granulate comprising granules made up of 40-99 wt. % of lactose particles and 1-60 wt. % of a binding component that holds together the lactose particles within the granules. Said granules have a mass weighted average diameter of 50-500 ?m and said binding component is a solid dispersion or a solid solution of 10-75 wt. % of a cannabinoid in 25-80 wt. % of a lipophilic matrix. The lipophilic matrix contains at least 80 wt. % sucrose fatty acid mono-ester, the fatty acid residue being selected from C8-C18 fatty acids. The aforementioned granulate can be processed into oral dosage units in the form of tablets for oral delivery. The invention further provides a method for the manufacture of the granulate.

Abstract: Applicator for delivering an occluding compound in a fallopian tube includes a lumen extending between a proximal end connectable to a dispenser for containing uncured occluding compound, and a distal end. A spiral wire with a first end is connected to the distal end of the lumen and a free second end. A disconnecting member is configured to disconnect the spiral wire from the distal end. An actuator is configured to actuate the disconnecting member. The distal end of the lumen can be inserted into the fallopian tube. The spiral wire functions as a guide wire. The curable compound embeds the spiral wire. The actuator can be actuated to disconnect the embedded spiral wire from the distal end of the lumen.

Abstract: A composition for use in occluding a body duct, such as female sterilization or blocking the urethra, in a living creature with a plug prepared in situ from a composition of an addition curable polysiloxane system.

Abstract: A composition for use in treating soft tissue in a living creature with a bulking material prepared in situ from a composition of an addition curable polysiloxane system.

Abstract: A mixing device for bone cement is provided. The mixing device includes a mixing handle, an housing, and a mixing paddle. The mixing handle having a rod, where at least portions of the rod are in tubular form with monomer inside of the rod. The housing has a mixing chamber in which the monomer and a powder are miscible. The mixing paddle is arranged in the mixing chamber and is movable via the rod.

Abstract: The invention relates generally to treatments of disordered bony structures, in particular to vertebroplasty compositions and methods and, more specifically, to treating vertebral bodies in living creatures, in particular, human beings and also compositions suitable for use in such methods and preparation and use of such compositions. According to the invention the composition to be used is an addition curable polysiloxane system.

Abstract: A device for preparing and ejecting polymeric cement made from at least two pre-packaged components comprises a tubular vessel including a first axial end wall having a closed outlet, and a second axial end wall having an aperture. A first starting component of the polymeric cement is present inside said tubular vessel near the first axial end wall. A shaft extends through said aperture of the second axial end wall. A piston element comprises a closed container filled with a second starting component of the polymeric cement. The piston element is selectively lockable to the shaft. The container has a bore and is slidingly engaged upon said shaft. An agitator element is secured to one end of the shaft. Furthermore opening means for providing an opening in the closed container are provided.